These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 38266541

  • 21. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A, Wittekind C.
    Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
    [Abstract] [Full Text] [Related]

  • 22. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G.
    Cancer Control; 2020 Jan; 27(1):1073274820983013. PubMed ID: 33356500
    [Abstract] [Full Text] [Related]

  • 23. Past, Present, and Future Management of Localized Biliary Tract Malignancies.
    Li J, Rocha FG, Mayo SC.
    Surg Oncol Clin N Am; 2023 Jan; 32(1):83-99. PubMed ID: 36410923
    [Abstract] [Full Text] [Related]

  • 24. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.
    Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, Koshiol J.
    Cancer; 2019 May 01; 125(9):1489-1498. PubMed ID: 30645774
    [Abstract] [Full Text] [Related]

  • 25. Hepatobiliary cancers, version 2.2014.
    Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H.
    J Natl Compr Canc Netw; 2014 Aug 01; 12(8):1152-82. PubMed ID: 25099447
    [Abstract] [Full Text] [Related]

  • 26. Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis.
    Cheung KS, Yeung YWM, Wong WS, Li B, Seto WK, Leung WK.
    Cancer Med; 2023 Jan 01; 12(1):557-568. PubMed ID: 35698295
    [Abstract] [Full Text] [Related]

  • 27. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
    Teh M, Wee A, Raju GC.
    Cancer; 1994 Sep 01; 74(5):1542-5. PubMed ID: 7520348
    [Abstract] [Full Text] [Related]

  • 28. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
    Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H.
    Cell Rep; 2019 Apr 23; 27(4):1265-1276.e4. PubMed ID: 31018139
    [Abstract] [Full Text] [Related]

  • 29. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
    McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, Okusaka T, Knox JJ, Wagner AD, André T, Cunningham D, Moehler M, Jensen LH, Koeberle D, Bekaii-Saab T, Bridgewater J, Valle JW.
    J Hepatol; 2020 Nov 23; 73(5):1109-1117. PubMed ID: 32446715
    [Abstract] [Full Text] [Related]

  • 30. Surgical Resection Alone is Associated With Higher Long-Term Survival Than Multiagent Chemotherapy Alone for Patients With Localized Biliary Tract Cancers.
    Elshami M, Ammori JB, Hardacre JM, Selfridge JE, Bajor D, Mohamed A, Chakrabarti S, Mahipal A, Winter JM, Ocuin LM.
    J Surg Res; 2024 Mar 23; 295():705-716. PubMed ID: 38141457
    [Abstract] [Full Text] [Related]

  • 31. Biliary tract malignancies: a population-based study on incidence, prognosis and management of patients.
    Juliusson G, Jonasson JG, Jonsdottir SB, Garcia HG, Olafsdottir E, Möller PH, Björnsson ES.
    Scand J Gastroenterol; 2016 Dec 23; 51(12):1520-1525. PubMed ID: 27553174
    [Abstract] [Full Text] [Related]

  • 32. Assessment of endoscopic aspiration cytology and endoscopic retrograde cholangio-pancreatography in patients with cancer of the hepato-biliary tract. Part II.
    Harada H, Sasaki T, Yamamoto N, Tanaka J, Tomiyama Y.
    Gastroenterol Jpn; 1977 Dec 23; 12(1):59-64. PubMed ID: 863180
    [Abstract] [Full Text] [Related]

  • 33. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, Lee KT, Lee JK.
    Scand J Gastroenterol; 2019 Jun 23; 54(6):740-745. PubMed ID: 31136212
    [Abstract] [Full Text] [Related]

  • 34. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A, Semba T, Sato R, Nobusue H, Sugihara E, Takaishi H, Kanai T, Saya H, Arima Y.
    Cancer Sci; 2021 May 23; 112(5):1822-1838. PubMed ID: 33068050
    [Abstract] [Full Text] [Related]

  • 35. Left hemihepatectomy and caudate lobectomy and complete extrahepatic bile duct resection using transduodenal approach for hilar cholangiocarcinoma arsing from biliary papillomatosis.
    Kim JK, Hwang HK, Park JS, Cho SI, Yoon DS, Chi HS.
    J Surg Oncol; 2008 Aug 01; 98(2):139-42. PubMed ID: 18521837
    [Abstract] [Full Text] [Related]

  • 36. Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study.
    Rahman R, Ludvigsson JF, von Seth E, Lagergren J, Bergquist A, Radkiewicz C.
    Eur J Cancer; 2022 Nov 01; 175():291-298. PubMed ID: 36174301
    [Abstract] [Full Text] [Related]

  • 37. Pathological characteristics of early to advanced gallbladder carcinoma and extrahepatic cholangiocarcinoma.
    Kijima H, Wu Y, Yosizawa T, Suzuki T, Tsugeno Y, Haga T, Seino H, Morohashi S, Hakamada K.
    J Hepatobiliary Pancreat Sci; 2014 Jul 01; 21(7):453-8. PubMed ID: 24591403
    [Abstract] [Full Text] [Related]

  • 38. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    Lee JK, Capanu M, O'Reilly EM, Ma J, Chou JF, Shia J, Katz SS, Gansukh B, Reidy-Lagunes D, Segal NH, Yu KH, Chung KY, Saltz LB, Abou-Alfa GK.
    Br J Cancer; 2013 Aug 20; 109(4):915-9. PubMed ID: 23900219
    [Abstract] [Full Text] [Related]

  • 39. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A, Ricci AD, Brandi G.
    Expert Opin Investig Drugs; 2021 Apr 20; 30(4):317-324. PubMed ID: 33054456
    [Abstract] [Full Text] [Related]

  • 40. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L, Chen W, Liang P, Hu W, Zhang K, Shen S, Chen J, Zhang Z, Chen B, Han Y, Meng F, DeMorrow S, Yin X, Lai J, Liang L.
    Dig Dis Sci; 2015 May 20; 60(5):1273-83. PubMed ID: 25487191
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.